Neil Singla, MD
Chief Scientific Officer

Dr. Neil Singla, a board-certified anesthesiologist, is the founder and Chief Scientific Officer of Lotus Clinical Research. Since its inception in 2001, Dr. Singla has served in several roles within the organization including: Research Coordinator, Sub-Investigator, Principal Investigator, Coordinating Investigator, and Chief Scientific Officer.

In his capacity as CSO for Lotus Clinical Research, Dr. Singla has had the opportunity to interact frequently with the FDA’s Analgesics Division on behalf of clients and to play a significant role in guiding development strategies for dozens of putative analgesic agents. In the company’s 18-year history, Dr. Singla and Lotus Clinical Research have played a significant role in bringing several molecules to market.

Dr. Singla has published extensively and is a frequent lecturer for physicians, pharmaceutical companies, and medical research institutes throughout the country. He currently chairs the Analgesic Clinical Trials Shared/Special Interest Group at the International Association for the Study of Pain (IASP), chaired the Clinical Trials Shared Interest Group at the American Pain Society (APS) through 2019, chairs the annual Conference on Analgesic Clinical Trials, which aims to help experts advance best practices in analgesic drug development, as well as, serving on the Clinical Research Committee at Huntington Hospital.

The main focus of Dr. Singla’s academic endeavors has been to analyze and understand how the inherent variability in subjective endpoint analgesic clinical trials can be minimized. As a result, he has developed novel techniques for patient education designed to minimize variability, reduce placebo response, and increase effect size.

Sonia Kaur, DO
Medical Director

Dr. Sonia Kaur is a board-certified physician with over 15 years of experience in analgesic research. She has served as the medical monitor, principal investigator, or sub investigator on over 200 pain studies. In her current capacity, Dr. Kaur provides medical oversight of the Lotus Clinical Research investigative team to ensure proper study conduct and optimal patient safety, and is responsible for liaising with the sponsor’s chief medical officer. She spearheads Lotus Clinical Research’s internal placebo response staff education training program. From 2008-2011, Dr. Kaur served as the chairman of the Glendale Adventist Hospital IRB.

Lee Simon, MD, FACP, FACR
Principal Advisor, Osteoarthritis Research

Dr. Lee Simon is responsible for providing scientific leadership on the design and conduct of osteoarthritis clinical trials. Dr. Simon brings a breadth of experience and expertise in analgesic clinical research, as he has been a clinical Rheumatologist for 25 years and previously served as the Division Director of the Arthritis, Analgesic & Ophthalmologic Drug Product Division at the US Food and Drug Administration (FDA) Center for Drug Evaluation and Research. He has experience as an NIH funded investigator and has served two terms on the Board of Directors of the American College of Rheumatology (ACR). Dr. Simon is on the editorial boards of multiple journals and has authored more than 110 original publications, reviews, and book chapters.

Jeanne Ashton-Strain
Vice President, Data Services

Jeanne has over 20 years CRO experience including leadership of Data Management, Biostatistics, Statistical Programming, Medical Writing, Interactive Response Technology and Document Management & Publishing departments globally. At Lotus, Jeanne is responsible for overseeing the Data Management, Biostatistics, Medical Writing and Systems Integration Teams. She spent her initial 16 years at a major pharmaceutical company and has experience in clinical trials from Phase I through IV, post approval studies and multitude of therapy areas. She has overseen operations on three continents and seven countries. Jeanne also has significant experience systems development, validation and implementation. Jeanne holds a BS in Biochemistry from Rutgers University and a Masters from Seton Hall University.

Anne Arriaga
Chief Operating Officer

Anne Arriaga joined Lotus in 2008 and has since assembled a top-quality team of investigators, project managers, and study coordinators. She has managed the clinical operations and execution of over 500 trials, of which over 300 were analgesic trials.  She has a bachelor’s degree in healthcare administration, a degree in nursing, and post graduate training in clinical research management and project management. Prior to joining Lotus, Mrs. Arriaga served for 10 years as the Vice President of Clinical Operations for a 120-bed Phase 1 unit.

 

Eric Guitard, PMP
Director, Systems Integration

Eric Guitard is responsible for managing the information technology team. His responsibilities include managing all GxP systems such as eTMF, CTMS, file management and desktop management. For seven years prior to joining Lotus Clinical Research, he managed the internal CRO functionalities of a biomedical company specializing in pain management. Mr. Guitard was responsible for all project management, data management, vendor management, and clinical program development. He holds a bachelor’s degree in business administration with a major in computer science from the University of Montreal and is also a Certified Project Professional Manager from the Project Management Institute.

Christopher Bowman
Director, Quality Operations

Christopher Bowman has over 15 years of experience in clinical research spanning regulatory compliance, quality assurance, and clinical management of Phase I through Phase IV studies. Prior to joining Lotus, he held positions as the Director of Clinical Operations for a clinical and regulatory consulting firm and served as the Director of Quality Operations for a large Phase I-IV clinical trial center. Mr. Bowman has extensive knowledge in Federal Regulations and GCP/ICH guidance with over 12 years conducting GCP compliance audits including investigational sites, sponsors, CROs, clinical vendors, trial master files, IRBs, and FDA readiness visits both in the U.S. and abroad.